Avidity Biosciences Analyst Ratings

BenzingaJan 10 20:36 · Ratings

H.C. Wainwright Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $72

Futu NewsJan 10 20:34 · Ratings

Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75

Futu NewsJan 9 18:37 · Ratings

Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)

TipRanksJan 9 17:50 · Ratings

Avidity Biosciences Plans to Submit First Biologics License Application This Year

MT NewswiresJan 9 00:23

Express News | Avidity Biosciences: Accelerated Approval Path Confirmed for Del-Zota; Bla Submission Planned for Year End 2025

BreakingsJan 8 22:03